Her primary areas of investigation include Receptor, Interleukin 21, Molecular biology, Lymphokine-activated killer cell and Natural killer cell. Her Receptor research incorporates themes from NK cell activation and Monoclonal antibody. Interleukin 21 is a primary field of her research addressed under Immunology.
Her biological study focuses on Human leukocyte antigen. Her research in Lymphokine-activated killer cell focuses on subjects like Cell biology, which are connected to Cell, Co-receptor, Ligand and Cytotoxicity. Her Natural killer cell research includes themes of Major histocompatibility complex and CD48.
The scientist’s investigation covers issues in Immunology, Human leukocyte antigen, Receptor, Molecular biology and Interleukin 21. Her Immunology study incorporates themes from Hematopoietic stem cell transplantation and Transplantation. Her study in Human leukocyte antigen is interdisciplinary in nature, drawing from both Monoclonal antibody, CD8, Major histocompatibility complex and Virology.
Her studies in Receptor integrate themes in fields like Cell, Natural killer cell, Cytotoxicity and Cell biology. Her work carried out in the field of Molecular biology brings together such families of science as Cell culture, Transfection, Transmembrane protein, Complementary DNA and Antibody. Her biological study spans a wide range of topics, including KIR2DL1, Interleukin 12, Lymph node and Innate immune system.
Immunology, Human leukocyte antigen, Hematopoietic stem cell transplantation, Receptor and Transplantation are her primary areas of study. Her work in Interleukin 21, T cell, NK-92, Human cytomegalovirus and HLA-C are all subfields of Immunology research. Her research integrates issues of Signal transduction and CD48 in her study of Interleukin 21.
Her work in Human leukocyte antigen covers topics such as Major histocompatibility complex which are related to areas like CD8, T-cell receptor and HLA-E. Her Hematopoietic stem cell transplantation research includes elements of Leukemia, Acute leukemia and Donor selection. Michela Falco has researched Receptor in several fields, including Cell, Cell biology, Effector and Immune system.
Her main research concerns Immunology, Human leukocyte antigen, Receptor, Hematopoietic stem cell transplantation and Lymphokine-activated killer cell. Particularly relevant to Innate lymphoid cell is her body of work in Immunology. Her Receptor research is multidisciplinary, incorporating elements of Cell, Cytotoxic T cell and Immune system.
Her Hematopoietic stem cell transplantation research incorporates elements of Leukemia, Acute leukemia and Incidence. She's looking at Lymphokine-activated killer cell as part of her Interleukin 12 and Interleukin 21 and Lymphokine-activated killer cell study. Her Interleukin 12 research focuses on subjects like Natural killer cell, which are linked to Congenital cytomegalovirus infection, Natural killer T cell and B cell.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
X-Linked Lymphoproliferative Disease 2b4 Molecules Displaying Inhibitory Rather than Activating Function Are Responsible for the Inability of Natural Killer Cells to Kill Epstein-Barr Virus–Infected Cells
Silvia Parolini;Cristina Bottino;Michela Falco;Raffaella Augugliaro.
Journal of Experimental Medicine (2000)
CpG and double-stranded RNA trigger human NK cells by Toll-like receptors: Induction of cytokine release and cytotoxicity against tumors and dendritic cells
Simona Sivori;Michela Falco;Mariella Della Chiesa;Simona Carlomagno.
Proceedings of the National Academy of Sciences of the United States of America (2004)
CD56brightCD16− Killer Ig-Like Receptor− NK Cells Display Longer Telomeres and Acquire Features of CD56dim NK Cells upon Activation
Chiara Romagnani;Kerstin Juelke;Michela Falco;Barbara Morandi.
Journal of Immunology (2007)
The natural killer cell receptor specific for HLA-A allotypes: a novel member of the p58/p70 family of inhibitory receptors that is characterized by three immunoglobulin-like domains and is expressed as a 140-kD disulphide-linked dimer.
D Pende;R Biassoni;C Cantoni;S Verdiani.
Journal of Experimental Medicine (1996)
HLA-C is the inhibitory ligand that determines dominant resistance to lysis by NK1- and NK2-specific natural killer cells.
Marco Colonna;Giovanna Borsellino;Michela Falco;Giovan Battista Ferrara.
Proceedings of the National Academy of Sciences of the United States of America (1993)
Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity
Daniela Pende;Stefania Marcenaro;Michela Falco;Stefania Martini.
The human leukocyte antigen (HLA)-C-specific "activatory" or "inhibitory" natural killer cell receptors display highly homologous extracellular domains but differ in their transmembrane and intracytoplasmic portions.
Roberto Biassoni;Claudia Cantoni;Michela Falco;Simonetta Verdiani.
Journal of Experimental Medicine (1996)
Analysis of the receptor-ligand interactions in the natural killer-mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112).
Daniela Pende;Grazia Maria Spaggiari;Stefania Marcenaro;Stefania Martini.
Gntb-A, a Novel Sh2d1a-Associated Surface Molecule Contributing to the Inability of Natural Killer Cells to Kill Epstein-Barr Virus–Infected B Cells in X-Linked Lymphoproliferative Disease
Cristina Bottino;Michela Falco;Silvia Parolini;Emanuela Marcenaro.
Journal of Experimental Medicine (2001)
HLA-haploidentical stem cell transplantation after removal of αβ+ T and B cells in children with nonmalignant disorders
Alice Bertaina;Pietro Merli;Sergio Rutella;Sergio Rutella;Daria Pagliara.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: